Robeco Institutional Asset Management B.V. Lowers Position in Edwards Lifesciences Co. (NYSE:EW)

Robeco Institutional Asset Management B.V. cut its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 9.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 274,411 shares of the medical research company’s stock after selling 30,176 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Edwards Lifesciences were worth $20,315,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of EW. Wellington Management Group LLP grew its holdings in shares of Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Edwards Lifesciences by 475.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after acquiring an additional 3,506,886 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in Edwards Lifesciences by 239.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock valued at $243,745,000 after acquiring an additional 2,606,950 shares during the period. Seilern Investment Management Ltd purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $109,490,000. Finally, Nordea Investment Management AB boosted its holdings in Edwards Lifesciences by 34.6% during the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after acquiring an additional 1,043,484 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Down 1.1 %

Shares of EW stock opened at $72.41 on Friday. The business’s 50 day moving average is $72.45 and its two-hundred day moving average is $70.09. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a market capitalization of $42.71 billion, a P/E ratio of 10.45, a price-to-earnings-growth ratio of 3.65 and a beta of 1.11. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 33,000 shares of company stock worth $2,195,180. 1.29% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

EW has been the subject of a number of research analyst reports. Barclays raised their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a report on Monday, December 2nd. The Goldman Sachs Group raised their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Robert W. Baird lowered their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Wolfe Research lowered Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target on the stock. in a research report on Thursday, January 16th. Finally, Citigroup increased their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $79.19.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.